Ductal carcinoma in situ, complexities and challenges

Journal of the National Cancer Institute

Volumn 96, Issue 12, 2004, Pages 906-920

  Leonard, Gregory D ^a   Swain, Sandra M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; MOLECULAR MARKER; PLACEBO; TAMOXIFEN; WARFARIN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ENZYME INHIBITOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TUMOR MARKER;

BIOPSY TECHNIQUE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL STUDY; CLINICAL TRIAL; CORRELATION ANALYSIS; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG INDICATION; DRUG USE; HUMAN; INTERMETHOD COMPARISON; LABORATORY TEST; LUNG EMBOLISM; LYMPH NODE DISSECTION; MAMMOGRAPHY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PAGET NIPPLE DISEASE; PARTIAL MASTECTOMY; PATHOGENESIS; PATIENT CARE; PATIENT INFORMATION; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; RISK REDUCTION; STANDARD; STATISTICAL SIGNIFICANCE; STROKE; SURGICAL APPROACH; SURGICAL TECHNIQUE; TREATMENT INDICATION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; CANCER REGISTRY; FEMALE; LYMPH NODE METASTASIS; LYMPHADENECTOMY; PATHOLOGY; SEGMENTAL MASTECTOMY; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; ENZYME INHIBITORS; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MASTECTOMY, SEGMENTAL; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY, ADJUVANT; RECEPTORS, ESTROGEN; RISK FACTORS; SEER PROGRAM; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 2942672535     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh164     Document Type: Review

References (226)

1. Olivotto I, Levine M. Clinical practice guidelines for the care and treatment of breast cancer: the management of ductal carcinoma in situ. CMAJ 2001;165:912-3.
2. MacCarty WC. The histogenesis of cancer (carcinoma) of the breast and its clinical significance. Surg Gynecol Obstet 1913;17:441-59.
3. Bloodgood JC. Comedo carcinoma (or comedo-adenoma) of the female breast. Am J Cancer 1934;22:842-53.
4. Broders AC. Carcinoma in situ contrasted with benign penetrating epithelium. JAMA 1932;99:1670-4.
5. Gillis DA, Dockerty MB, Clagett OT. Preinvasive intraductal carcinoma of the breast. Surg Gynecol Obstet 1960;110:555-62.
6. Wellings SR, Jensen HM. On the origin and progression of ductal carcinoma in the human breast. J Natl Cancer Inst 1973;50:1111-6.
7. Ernster VL, Ballard-Barbash R, Barlow WE, Zheng Y, Weaver DL, Cutter G, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2002;94:1546-54.
8. Ernster VL, Barclay J. Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma. J Natl Cancer Inst Monogr 1997;22:151-6.
9. Debnath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK, Brugge JS. The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 2002;111:29-40.
10. Azzopardi JG. Problems in breast pathology. Philadelphia (PA): WB Saunders; 1979. p. 466.
11. Consensus conference on the classification of ductal carcinoma in situ. The Consensus Conference Committee. Cancer 1997;80:1798-1802.
12. Rosai J. Borderline epithelial lesions of the breast. Am J Surg Pathol 1991;15:209-21.
13. Lagios MD. Duct carcinoma in situ. Pathology and treatment. Surg Clin North Am 1990;70:853-71.
14. Bloom HJG, Richardson WW. Histologic grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957;11:359-77.
15. Lennington WJ, Jensen RA, Dalton LW, Page DL. Ductal carcinoma in situ of the breast. Heterogeneity of individual lesions. Cancer 1994;73: 118-24.
16. Scott MA, Lagios MD, Axelsson K, Rogers LW, Anderson TJ, Page DL. Ductal carcinoma in situ of the breast: reproducibility of histopathological subtype analysis. Hum Pathol 1997;28:967-73.
17. Bellamy CO, McDonald C, Salter DM, Chetty U, Anderson TJ. Noninvasive ductal carcinoma of the breast: the relevance of histologic categorization. Hum Pathol 1993;24:16-23.
18. Poller DN, Silverstein MJ, Galea M, Locker AP, Elston CW, et al. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erB-2 protein expression. Mod Pathol 1994;7:257-62.
19. Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, Blamey RW, et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995;345:1154-7.
20. Silverstein MJ, Lagios MD, Craig PH, Waisman JR, Lewinsky BS, Colburn WJ, et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer 1996;77:2267-74.
21. Silverstein MJ. The University of Southern California/Van Nuys Prognostic Index. In: Silverstein MJ, editor. Ductal carcinoma in situ of the breast. 2nd ed. Philadelphia PA: Lippincott, Williams & Wilkins; 2002. p. 459-73.
22. Ottesen GL, Graversen HP, Blichert-Toft M, Zedeler K, Andersen JA. Ductal carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group. Am J Surg Pathol 1992;16:1183-96.
23. Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver MJ, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994;11:167-80.
24. National Co-ordinating Group for Breast Screening Pathology. Pathology reporting in breast cancer screening. Sheffield (UK): NHSBSP Publications No. 3;1997. p. 22-7.
25. Tavassoli FA. Ductal carcinoma in situ: introduction of the concept of ductal intraepithelial neoplasia. Mod Pathol 1998;11:140-54.
26. Warnberg F, Casalini P, Nordgren H, Bergkvist L, Holmberg L, Menard S. Ductal carcinoma in situ of the breast: a new phenotype classification system and its relation to prognosis. Breast Cancer Res Treat 2002;73: 215-21.
27. Badve S, A'Hern RP, Ward AM, Millis RR, Pinder SE, Ellis IO, et al. Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: a comparative study with long follow-up. Hum Pathol 1998;29:915-23.
28. American Joint Committee on Cancer. Cancer Staging Manual. 6th ed. New York (NY): Springer-Verlag; 2002. p. 223-40.
29. Padmore RF, Fowble B, Hoffman J, Rosser C, Hanlon A, Patchefsky AS. Microinvasive breast carcinoma. Clinicpathologic analysis of a single institution experience. Cancer 2000;88:1403-9.
30. Silver SA, Tavassoli FA. Mammary ductal carcinoma in situ with micro-invasion. Cancer 1998;82:2382-90.
31. Silverstein MJ, Waisman JR, Gamagami P, Gierson ED, Colburn WJ, Rosser RJ, et al. Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment choice. Cancer 1990;66:102-8.
32. Silverstein MJ, Lagios MD. Ductal carcinoma in situ with microinvasion. In: Silverstein MJ, editor. Ductal carcinoma in situ of the breast. 2nd ed. Philadelphia (PA): Lippincott, Williams & Wilkins; 2002. p. 523-9.
33. Schnitt SJ. Microinvasive carcinoma of the breast: a diagnosis in search of a definition. Adv Anat Pathol 1998;5:367-72.
34. Lagios MD, Margolin FR, Westdahl PR, Rose MR. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989;63:618-24.
35. Amichetti M, Caffo O, Richetti A, Zim G, Rigon A, Antonello M, et al. Ten-year results of treatment of ductal carcinoma in situ (DCIS) of the breast with conservative surgery and radiotherapy. Eur J Cancer 1997;33: 1559-65.
36. Ashikari R, Hadju SI, Robbins GF. Intraductal carcinoma of the breast (1960-1969). Cancer 1971;28:1182-7.
37. Brown PW, Silverman J, Owens E, Tabor DC, Terz JJ, Lawrence W Jr. Intraductal "noninfiltrating" carcinoma of the breast. Arch Surg 1976;111: 1063-7.
38. Carter D, Smith RR. Carcinoma in situ of the breast. Cancer 1977;40: 1189-93.
39. Dimpfl T, Genz T, Hecher C, Jung E, Kindermann G. Intraductal carcinoma (DCIS) of the breast. Risk-adapted tumor surgery with axillary lymphadenectomy? Eur J Gynecol Oncol 1996;17:104-9.
40. Fisher ER, Sass R, Fisher B, Wickerham L, Paik SM. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6). I. Intraductal carcinoma (DCIS). Cancer 1986;57:197-208.
41. Gump FE, Jicha DL, Ozello L. Ductal carcinoma in situ (DCIS): a revised concept. Surgery 1987;102:790-5.
42. Parker RG, Berbigler D, Rees K, Leung KM, Legorreta AP. Axillary node dissection in ductal carcinoma in situ. Am J Clin Oncol 1998;21:109-10.
43. Patchefsky AS, Schwartz GF, Finkelstein SD, Prestipino A, Sohn SE, Singer JS, et al. Heterogeneity of intraductal carcinoma of the breast. Cancer 1989;63:731-41.
44. Recht A, Danoff BS, Solin LJ, Schnitt S, Connolly J, Botnick L, et al. Intraductal carcinoma of the breast: results of treatment with excisional biopsy and irradiation. J Clin Oncol 1985;3:1339-43.
45. Rosner D, Bedwani RN, Vana J, Baker HW, Murphy GP. Noninvasive breast carcinoma: results of a national survey by the American College of Surgeons. Ann Surg 1980;192:139-47.
46. Schuh ME, Nemoto T, Penetrante RB, Rosner D, Dao TL. Intraductal carcinoma. Analyzing presentation, pathologic findings and outcome of disease. Arch Surg 1986;121:1303-7.
47. Solin LJ, Recht A, Fourquet A, Kurtz J, Kuske R, McNeese M, et al. Ten-year results of breast-conserving surgery and definitive irradiation for intraductal carcinoma (ductal carcinoma in situ) of the breast. Cancer 1991;68:2337-44.
48. Sunshine JA, Moseley HS, Fletcher WS, Krippaehne WW. Breast carcinoma in situ: a retrospective review of 112 cases with a minimum of 10-year follow-up. Am J Surg 1985;150:44-51.
49. von Rueden DG, Wilson RE. Intraductal carcinoma of the breast. Surg Gynecol Obstet 1984;158:105-11.
50. Akhtar S, Zablow A, Michaelson RA, Hutter RV, Leitner SP. Predictors of axillary lymph node metastases in small (one centimeter or less) T1a,b primary breast cancer [abstract 458]. Proc ASCO 1998;17:120a.
51. Kinne DW, Petrek JA, Osborne MP, Fracchia AA, DePalo AA, Rosen PP. Breast carcinoma in situ. Arch Surg 1989;124:33-6.
52. Jimenez RE, Visscher DW. Clinicopathologic analysis of microscopically invasive breast carcinoma. Hum Pathol 1998;29:1412-9.
53. Le Bouedec G, Penault-Llorca F, de Latour M, Joubert J, Kauffmann P, Pomel C, et al. Microinvasive carcinoma of the breast. Role of axillary lymph node dissection. J Gynecol Obstet Biol Reprod 1999;28:10-6.
54. Prasad ML, Osborne MP, Giri DD, Hoda SA. Microinvasive carcinoma (T1mic) of the breast: clinicopathologic profile of 21 cases. Am J Surg Pathol 2000;24:422-8.
55. Rosner D, Lane WW, Penetrante R. Ductal carcinoma in situ with microinvasion. A curable entity using surgery alone without need for adjuvant therapy. Cancer 1991;67:1498-503.
56. Schwartz GF, Feig SA, Rosenberg AL, Patchefsky AS, Schwartz AB. Staging and treatment of clinically occult breast cancer. Cancer 1984;53: 1379-84.
57. Simpson T, Thirlby RC, Dail DH. Surgical treatment of ductal carcinoma in situ of the breast: 10- to 20-year follow up. Arch Surg 1992;127:468-72.
58. Solin LJ, Fowble BL, Yeh IT, Kowalyshyn MJ, Schultz DJ, Weiss MC, et al. Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive irradiation. Int J Radiat Oncol Biol Phys 1992;23:961-8.
59. Wong JH, Kopald KH, Morton DL. The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer. Arch Surg 1990;125:1298-1301.
60. Zavotsky J, Hansen N, Brennan MB, Turner RR, Giuliano AE. Lymph node metastasis from ductal carcinoma in situ with microinvasion. Cancer 1999;85:2439-43.
61. Wasserberg N, Morgenstern S, Schacter J, Fenig E, Lelcuk S, Gutman H. Risk factors for lymph node metastases in breast ductal carcinoma in situ with minimal invasive component. Arch Surg 2002;137:1249-52.
62. de Mascarel I, MacGrogan G, Mathoulin-Pelissier S, Soubeyran I, Picot V, Coindre JM. Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas. Cancer 2002;94:2134-42.
63. Knutzen AM, Gisvold JJ. Likelihood of malignant disease for various categories of mammographically detected, nonpalpable breast lesions. Mayo Clinic Proc 1993;68:454-60.
64. Holland R, Hendricks JH. Microcalcifications associated with ductal carcinoma in situ: mammographic-pathologic correlation. Semin Diagn Pathol 1994;11:181-92.
65. Slanetz PJ, Giardino AA, Oyama T, Koerner FC, Halpern Ef, Moore RH. Mammographic appearance of ductal carcinoma in situ does not reliably predict histologic subtype. Breast J 2001;7:417-21.
66. Tabar L, Gad A, Parsons WC, Neeland DB. Marnmographic appearances of in situ carcinomas. In: Silverstein MJ editor. Ductal carcinoma in situ of the breast. 1st ed. Baltimore (MD): Williams and Wilkins; 1997. p.95-117.
67. Holland R, Hendricks JH., Verbeek ALM, Mravunac M, Schuurmans Stekhoven JH. Extent, distribution, and mammographic/histologic correlations of breast ductal carcinoma in situ. Lancet 1990;335:519-22.
68. Viehweg P, Lampe D, Buchmann J, Heywang-Kobrunner SH. In situ and minimally invasive breast cancer: morphologic and kinetic features on contrast-enhanced MR imaging. MAGMA 2000;11:129-37.
69. Orel SG, Mendonca MH, Reynolds C, Schnall MD, Solin LJ, Sullivan DC. MR imaging of ductal carcinoma in situ. Radiology 1997;202:413-20.
70. Soderstrom CE, Harms SE, Copit DS, Evans WP, Savino DA, Krakos PA. Three-dimensional RODEO breast MR imaging of lesions containing ductal carcinoma in situ. Radiology 1996;201:427-32.
71. Gilles R, Zafrani B, Guinebretiere JM, Meunier M, Lucidarme O, Tardivon AA. Ductal carcinoma in situ: MR imaging - histopathologic correlation. Radiology 1995;196:415-19.
72. Ottinetti A, Sapino A. Morphometric evaluation of microvessels surrounding hyperplastic and neoplastic mammary lesions. Breast Cancer Res Treat 1988;11:241-8.
73. Hwang ES, Kinkel K, Esserman LJ, Lu Y, Weidner N, Hylton NM. Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity. Ann Surg Oncol 2003;10:381-8.
74. Bijker N, Rutgers EJ, Peterse JL, Fentiman IS, Julien JP, Duchateau L, et al. Variations in diagnostic and therapeutic procedures in a multicentre, randomized clinical trial (EORTC 10853) investigating breast-conserving treatment for DCIS. Eur J Surg Oncol 2001;27:135-40.
75. Winchester DP, Strom EA. Standards for diagnosis and management of ductal carcinoma in situ (DCIS) of the breast. American College of Radiology, American College of Surgeons, College of American Pathologists, Society of Surgical Oncology. CA Cancer J Clin 1998;48:108-28.
76. Parker SH, Burbank F, Jackman RJ, Percutaneous large-core biopsy: a multi-institutional study. Radiology 1994;193:359-64.
77. Burbank F. Stereotactic breast biopsy of atypical ductal hyperplasia and ductal carcinoma in situ lesions: improved accuracy with directional, vacuum-assisted biopsy. Radiology 1997;202:843-7.
78. Lee CH, Carter D, Philpotts LE, Couce ME, Horvath LJ, Lange RC, et al. Ductal carcinoma in situ diagnosed with stereotactic core needle biopsy: can invasion be predicted? Radiology 2000;217:466-70.
79. Wrensch MR, Petrakis NL, Miike R, King EB, Chew K, Neuhaus J, et al. Breast cancer risk in women with abnormal cytology in nipple aspirates of breast fluid. J Natl Cancer Inst 2001;93:1791-8.
80. Dooley WC, Ljung BM; Veronesi U, Cazzaniga M, Elledge RM, O'Shaughnessy JA, et al. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst 2001;93:1624-32.
81. Fabian CJ, Kimler BF, Zalles CM, Klemp JR, Kamel S, Zeiger S, et al. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst 2000;92: 1217-27.
82. Krishnamurthy S, Sneige N, Thompson PA, Marcy SM, Singeltary SE, Cristofanilli M, et al. Nipple aspirate fluid cytology in breast carcinoma. Cancer 2003;99:97-104.
83. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer Statistics, 2004. CA Cancer J Clin 2004;54:8-29.
84. Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 1996;275:913-8.
85. Alexander FE, Anderson TJ, Brown HK, Forrest AP, Hepburn W, Kirkpatrick AE, et al. The Edinburgh randomized trial of breast cancer screening: results after 10 years of follow-up. Br J Cancer 1994;70:542-8.
86. Thomas BA, Price J, Boulter PS. The Guildford Breast Screening Project. Clin Oncol 1983;9:121-9.
87. 16-year mortality from breast cancer in the UK trial of Early Detection of Breast Cancer. Lancet 1999;353:1909-14.
88. The frequency of breast cancer screening: results from the UKCCCR Randomized Trial. United Kingdom Co-ordinating Committee on Cancer Research. Eur J Cancer 2002;38:1458-64.
89. Miller AB, To T, Baines CJ, Wall C. The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40-49 years. Ann Intern Med 2002;137(5 Part 1):305-12.
90. Miller AB, To T, Baines CJ, Wall C. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years. J Natl Cancer Inst 2000;92:1490-9.
91. Olivotto IA, Bancej C, Goel V, Snider J, McAuley RG, Irvine B, et al. Waiting times from abnormal breast screen to diagnosis in 7 Canadian provinces. CMAJ 2001;165:277-83.
92. Tabar L, Vitak B, Chen HH, Duffy SW, Yen MF, Chiang CF, et al. The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiol Clin North Am 2000;38:625-51.
93. Andersson I, Aspegren K, Janzon L, Landberg T, Lindholm K, Linell F, et al. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. BMJ 1988;297:943-8.
94. Frisell J, Lidbrink E, Hellstrom L, Rutqvist LE. Followup after 11 years - update of mortality results in the Stockholm mammographic screening trial. Br Cancer Res Treat 1997;45:263-70.
95. Bjurstam N, Bjorneld L, Duffy SW, Smith TC, Cahlin E, Eriksson O, et al. The Gothenburg Breast Screening Trial. First results on mortality, incidence, and mode of detection for women ages 39-49 years at randomization. Cancer 1997;80:2091-9.
96. Chu KC, Smart CR, Tarone RE. Analysis of breast cancer mortality and stage distribution by age for the Health Insurance Plan clinical trial. J Natl Cancer Inst 1988;80:1125-32.
97. Bobo JK, Lee NC, Thames SF. Findings from 752,081 clinical breast examinations reported to a national screening program from 1995 through 1998. J Natl Cancer Inst 2000;92:971-6.
98. May DS, Lee NC, Nadel MR, Henson RM, Miller DS. The National Breast and Cervical Cancer Early Detection Program: report on the first 4 years of mammography provided to medically underserved women. AJR Am J Roentegenol 1998;170:97-104.
99. White E, Lee CY, Kristal AR. Evaluation of the increase in breast cancer incidence in relation to mammography use. J Natl Cancer Inst 1990;82: 1546-52.
100. Feuer EJ, Wun LM. How much of the recent rise in breast cancer incidence can be explained by increases in mammography utilization? A dynamic population model approach. Am J Epidemiol 1992;136:1423-36.
101. Recht A, Rutgers EJ, Fentiman IS, Kurtz JM, Mansel RE, Sloane JP. The Fourth EORTC DCIS Consensus meeting (Chateau Marquette, Heemskerk, The Netherlands, 23-24 January 1998) - conference report. Eur J Cancer 1998;34:1664-9.
102. Hittmair AP, Lininger RA, Tavassoli FA. Ductal carcinoma in situ (DCIS) in the male breast. A morphologic study of pure DCIS and 30 cases of DCIS associated with invasive carcinoma - a preliminary report. Cancer 1998;83:2139-49.
103. Kramer WM, Rush BF Jr. Mammary duct proliferation in the elderly. Cancer 1973;31:130-7.
104. Jensen HR, Rice JR, Wellings SR. Preneoplastic lesions in the human breast. Science 1976;191:295-7.
105. Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst 1975;55:231-73.
106. Nielsen M, Jensen J, Andersen J. Precancerous and cancerous breast lesions during lifetime and at autopsy: a study of 83 women. Cancer 1984;54:612-5.
107. Alpers CE, Wellings SR. The prevalence of carcinoma in situ in normal and cancer-associated breasts. Hum Pathol 1985;16:796-807.
108. Bhathal PS, Brown RW, Lesueur GC, Russell IS. Frequency of benign and malignant breast lesions in 207 consecutive autopsies in Australian women. Br J Cancer 1985;51:271-8.
109. Bartow SA, Pathak DR, Black WC, Key CR, Teaf SR. Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer: a forensic autopsy study. Cancer 1987;60:2751-60.
110. Nielsen M, Thomsen JL, Primdahl S, Dyreborg U, Andersen JA. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer 1987;56:814-9.
111. Claus EB, Stowe M, Carter D. Breast carcinoma in situ: risk factors and screening pattern. J Natl Cancer Inst 2001;93:1811-7.
112. Kerlikowske K, Barclay J, Grady D, Sickles EA, Ernster V. Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. J Natl Cancer Inst 1997;89:76-82.
113. Brinton LA, Hoover R, Fraumeni JF Jr. Epidemiology of minimal breast cancer. JAMA 1983;249:483-7.
114. Weiss HA, Brinton LA, Brogan D, Coates RJ, Gammon MD, Malone KE, et al. Epidemiology of in situ and invasive breast cancer in women aged under 45. Br J Cancer 1996;73:1298-305.
115. Longnecker MP, Bernstein L, Paganini-Hill A, Enger SM, Ross RK. Risk factors for in situ breast cancer. Cancer Epidemiol Biomarkers Prev 1996;5:961-5.
116. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favourable histology: results of the Iowa Women's Health Study. JAMA 1999;281:2091-7.
117. Henrich JB, Kornguth PJ, Viscoli CM, Horwitz RI. Postmenopausal estrogen use and invasive versus in situ breast cancer risk. J Clin Epidemiol 1998;51:1277-83.
118. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274:137-42.
119. Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN. Menopausal estrogen and estrogen-progestin replacement therapy and the risk of breast cancer (United States). Cancer Causes Control 1994;5:491-500.
120. Dubin N, Hutter RV, Strax P, Fazzini EP, Schinella RA, Batang ES, et al. Epidemiology of minimal breast cancer among women screened in New York City. J Natl Cancer Inst 1984;73:1273-9.
121. Lambe M, Hsieh CC, Tsaih SW, Ekbom A, Trichopoulos D, Adami HO. Parity, age at first birth and the risk of carcinoma in situ of the breast. Int J Cancer 1998;77:330-2.
122. Trentham-Dietz A, Newcomb PA, Storer BE, Remington PL. Risk factors for carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 2000;9:697-703.
123. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy post menopausal women: The Womens Health Initiative Randomized Trial. JAMA 2003;289:3243-53.
124. White J, Levine A, Gustafson G, Wimbish K, Ingold J, Pettinga J, et al. Outcome and prognostic factors for local recurrence in mammographically detected ductal carcinoma in situ of the breast treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys 1995; 31:791-7.
125. Solin LJ, Kurtz J, Fourquet A, Amalric R, Recht A, Bornstein BA, et al. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 1996;14:754-63.
126. Lagios MD. The Lagios experience. In: Silverstein MJ, editor. Ductal carcinoma in situ of the breast. 2nd ed. Philadelphia (PA): Lippincott, Williams & Wilkins; 2002. p. 303-7.
127. Cheng L, Al-Kaisi NK, Gordon NH, Liu AY, Gebrail F, Shenk RR. Relationship between the size and margin status of ductal carcinoma in situ of the breast and residual disease. J Natl Cancer Inst 1997;89:1356-60.
128. Douglas-Jones AG, Logan J, Morgan JM, Johnson R, Williams R. Effect of margins of excision on recurrence after local excision of ductal carcinoma in situ of the breast. J Clin Pathol 2002;55:581-6.
129. Silverstein MJ, Lagios MD, Groshen S, Waisman J, Lewinsky BS, Martino S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999;340:1455-61.
130. Solin LJ, Yeh IT, Kurtz J, Fourquet A, Recht A, Kuske R, et al. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation. Correlation of pathologic parameters with outcome of treatment. Cancer 1993;71:2532-42
131. Goldstein NS, Vicini FA, Kestin LL, Thomas M. Differences in the pathologic features of ductal carcinoma in situ of the breast based on age. Cancer 2000;88:2553-60.
132. Wazer DE, Schmidt-Ulrich RK, Ruthazer R, DiPetrillo T, Boyle T, Kanski J, et al. The influence of age and extensive intraductal component histology upon breast lumpectomy margin assessment as a predictor of residual tumor. Int J Radiat Oncol Biol Phys 1999;45:885-91.
133. Miller NA, Chapman JA, Fish EB, Link MA, Fischell E, Wright B, et al. In situ duct carcinoma of the breast: clinical and histopathologic factors and association with recurrent carcinoma. Breast J 2001;7:292-302.
134. Warnberg F, Nordgren H, Bergkvist, Holmberg L. Tumor markers in breast carcinoma correlate with grade rather than with invasiveness. Br J Cancer 2001;85:869-74.
135. Fisher ER, Dignam J, Tan-Chiu E, Costantino J, Fisher B, Paik S, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of protocol B-17. Cancer 1999;86:429-38.
136. Bijker N, Peterse JL, Duchateau L, Julien JP, Fentiman IS, Duval C, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 2001;19:2263-71.
137. Fearon ER, Vogelstein B. A genetic model for colorectal carcinogenesis. Cell 1990;61:759-67.
138. Miller FR, Soule HD, Tait L, Pauley RJ, Wolman SR, Dawson PJ, et al. Xenograft model of progressive human proliferative breast disease. J Natl Cancer Inst 1993;85:1725-32.
139. Lakhani SR. The transition from hyperplasia to invasive carcinoma of the breast. J Pathol 1999;187:272-8.
140. Holland PA, Knox WF, Potten CS, Howell A, Anderson E, Baildam AD, et al. Assessment of hormone dependence of comedo ductal carcinoma in situ of the breast. J Natl Cancer Inst 1997;89:1059-65.
141. Gandhi A, Holland PA, Knox WF, Potten CS, Bundred NJ. Effects of a pure antiestrogen on apoptosis and proliferation within human breast ductal carcinoma in situ. Cancer Res 2000;60:4284-8.
142. Mommers EC, Poulin N, Sangulin J, Meijer CJ, Baak JP, van Diest PJ. Nuclear cytometric changes in breast carcinogenesis. J Pathol 2001; 193:33-9.
143. Dean L, Geschickter CF. Comedo carcinoma of the breast. Arch Surg 1938;36:225-34.
144. Kraus FT, Neubecker RD. The differential diagnosis of papillary tumors of the breast. Cancer 1962;15:444-55.
145. Farrow JH. Current concepts in the detection and treatment of the earliest of the early breast cancers. Cancer 1970;25:468-77.
146. Haagensen CD, Lane N, Lattes R. Neoplastic proliferation of the epithelium of the mammary lobules: adenosis, lobular hyperplasia, and small cell carcinoma. Surg Clin North Am 1972;52:497-524.
147. Millis RR, Thynne GS. In situ intraduct carcinoma of the breast: a long term follow-up study. Br J Surg 1975;62:957-62.
148. Betsill WL Jr, Rosen PP, Lieberman PH, Robbins GF. Intraductal carcinoma. Long term follow-up after treatment by biopsy only. JAMA 1978; 239:1863-7.
149. Rosen PP, Braun DW Jr, Kinne DE. The clinical significance of preinvasive breast carcinoma. Cancer 1980;46(4 Suppl):919-25.
150. Page DL, Dupont WD, Rogers LW, Landenberger M. Intraductal carcinoma of the breast: follow up after biopsy only. Cancer 1982;49:751-8.
151. Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 1995;76:1197-200.
152. Eusebi V, Feudale E, Foschini MP, Micheli A, Conti A, Riva C, et al. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol 1994;11:223-35.
153. Millikan R, Dressler L, Geradts J, Graham M. The need for epidemiologic studies of in-situ carcinoma of the breast. Breast Cancer Res Treat 1995;35:65-77.
154. Helin HJ, Helle MJ, Kallioniemi OP, Isola JJ. Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma. Correlation with histopathology and DNA flow cytometry. Cancer 1989;63:1761-7.
155. Giri DD, Dundas SA, Nottingham JF, Underwood JC. Oestrogen receptors in benign epithelial lesions and intraduct carcinomas of the breast: an immunohistological study. Histopathology 1989;15:575-84.
156. Barnes R, Masood S. Potential value of hormone receptor assay in carcinoma in situ of breast. Am J Clin Pathol 1990;94:533-7.
157. Malafa M, Chaudhuri B, Thomford NR, Chaudhuri PK. Estrogen receptors in ductal carcinoma in situ of breast. Am Surg 1990;56:436-9.
158. Bur ME, Zimarowski MJ, Schnitt SJ, Baker S, Lew R. Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer 1992; 69:1174-81.
159. Pallis L, Wilking N, Cedermark B, Rutqvist LE, Skoog L. Receptors for estrogen and progesterone in breast carcinoma in situ. Anticancer Res 1992;12:2113-6.
160. Chaudhuri B, Cristi KA, Mucci S, Malafa M, Chaudhuri PK. Distribution of estrogen receptor in ductal carcinoma in situ of the breast. Surgery 1993;113:134-7.
161. Wilbur DC, Barrows GH. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study. Mod Pathol 1993;6:114-20.
162. Poller DN, Snead DR, Roberts EC, Galea M, Bell JA, Gilmour A, et al. Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erBb-2 oncoprotein. Br J Cancer 1993;68:156-61.
163. Zafrani B, Leroyer A, Fourqurt A, Laurent M, Trophilme D, Validire P, et al. Mammographically-detected ductal in situ carcinoma of the breast analysed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity. Semin Diagn Pathol 1994;11:208-14.
164. Bobrow LG, Happerfield LC, Gregory WM, Millis RR. Ductal carcinoma in situ: assessment of necrosis and nuclear morphology and their association with biological markers. J Pathol 1995;176:333-41.
165. Leal CB, Schmitt FC, Bento MJ, Maia NC, Lopes CS. Ductal carcinoma in situ of the breast: histological categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53 and c-erbB-2 protein. Cancer 1995;75:2123-31.
166. Albonico G, Querzoli P, Feretti S, Magri E, Nenci I. Biophenotypes of breast carcinoma in situ defined by image analysis of biological markers. Path Res Pract 1996;192:117-23.
167. Bose S, Lesser ML, Norton L, Rosen PP. Immunophenotype of intraductal carcinoma. Arch Pathol Lab Med 1996;120:81-5.
168. Shoker BS, Jarvis C, Sibson DR, Walker C, Sloane JP. Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol 1999;188: 237-44.
169. Ottesen GL, Christensen IJ, Larsen JK, Larsen J, Baldetorp B, Linden T, et al. Carcinoma in situ of the breast: correlation of histopathology to immunohistochemical markers and DNA ploidy. Breast Cancer Res Treat 2000;60:219-26.
170. Claus EB, Chu P, Howe CL, Davison TL, Stern DF, Carter D, et al. Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors. Exp Mol Pathol 2001; 70:303-16.
171. Suo Z, Bjaamer A, Ottestad I, Nesland JM. Expression of EGFR family and steroid hormone receptors in ductal carcinoma in situ of the breast. Ultrastruct Pathol 2001;25:349-56.
172. Selim AGA, El-Ayat G, Wells CA. Androgen receptor expression in ductal carcinoma in situ of the breast: relation to oestrogen and progesterone receptors. J Clin Pathol 2002;55:14-6.
173. Allred DC, Bryant J, Land S, Paik S, Fisher E, Julian T, et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: Findings from NSABP Protocol B-24 [abstract 30]. Breast Cancer Res Treat 2002;76:S36.
174. Millis RR, Bobrow LG, Barnes DM. Immunohistochemical evaluation of biological markers in mammary carcinoma in situ: correlation with morphological features and recently proposed schemes for histological classification. The Breast 1996;5:113-22.
175. van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J,
176. Barnes DM, Bartkova J, Camplejohn RS, Gullick WJ, Smith PJ, Millis RR. Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? Eur J Cancer 1992;28: 644-8.
177. DiGiovanna MP, Chu P, Davison TL, Howe CL, Carter D, Claus EB, et al. Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates. Cancer Res 2002;62:6667-73.
178. Thor AD, Liu S, Edgerton S, Moore D 2nd, Kasowitz KM, Benz CC, et al. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol 2000;18:3230-9.
179. Chan KC, Knox WF, Gandhi A, Slamon DJ, Potten CS, Bundred NJ. Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation. Br J Surg 2001;88:412-8.
180. Elledge RM, Fuqua SAW, Clark GM, Pujol P, Allred DC. William L. McGuire Memorial Symposium. The role and prognostic significance of p53 gene alterations in breast cancer. Breast Cancer Res Treat 1993;27: 95-102.
181. Paredes J, Milanezi F, Viegas L, Amendoeira I, Schmitt F. P-cadherin expression is associated with high-grade ductal carcinoma in situ of the breast. Virchows Arch 2002;440:16-21.
182. Lee KS, Rha SY, Kim SJ, Kim JH, Rob JK, Kim BS, et al. Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression. Clin Exp Metastasis 1996;14:512-9.
183. Guidi AJ, Fischer L, Harris JR, Schnitt SJ. Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 1994;86:614-9.
184. Guidi AJ, Schnitt SJ, Fischer L, Tognazzi K, Harris JR, Dvorak HF, et al. Vasular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 1997;80:1945-53.
185. Engels K, Fox SB, Whitehouse RM, Gatter KC, Harris AL. Up-regulation of thymidine phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinoma in situ of the breast. J Pathol 1997;182:414-20.
186. Alle KM, Henshall SM, Field AS, Suthetland RL. Cyclin D1 is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin Cancer Res 1998;4:847-54.
187. Weinstat-Saslow D, Merino MJ, Manrow RE, Lawrence JA, Bluth RF, Wittenbel KD, et al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med 1995;1:1257-60.
188. Kuukasjarvi T, Tanner M, Pennanen S, Karhu R, Kallioniemi OP, Isola J. Genetic changes in intraductal breast cancer detected by comparative genomic hybridization. Am J Pathol 1997;150:1465-71.
189. O'Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC. Analysis of loss of heterozygosity in 399 premalignant breast cancer lesions at 15 genetic loci. J Natl Cancer Inst 1998;90:697-703.
190. Stratton MR, Collins N, Lakhani SR, Sloane JP. Loss of heterozygosity in ductal carcinoma in situ of the breast. J Pathol 1995;175:195-201.
191. Buerger H, Otterbach F, Simon R, Poremba C, Diallo R, Decker T, et al. Comparative genomic hybridization of ductal carcinoma in situ of the breast - evidence of multiple genetic pathways. J Pathol 1999;187:396-402.
192. Farabegoli F, Champene MH, Bieche I, Santini D, Ceccarelli C, Derenzini M, et al. Genetic pathways in the evolution of breast ductal carcinoma in situ. J Pathol 2002;196:280-6.
193. Glockner S, Lehmann U, Wilke N, Kleeberger W, Langer F, Kreipe H. Amplification of growth regulatory genes in intra-ductal breast cancer is associated with higher nuclear grade but not progression to invasiveness. Lab Invest 2001;81:565-71.
194. Lakhani SR, Chaggar R, Davies S, Jones C, Collins N, Odel C, et al. Genetic alterations in "normal" luminal and myoepithelial cells of the breast. J Pathol 1999;189:496-503.
195. Boecker W, Buerger H, Schmitz K, Ellis IA, van Diest PJ, Sinn HP, et al. Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns. J Pathol 2001;195:415-21.
196. Perou CM, Sorlie T, Elsen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
197. Allred DC, Wu Y, Tsimelzon A, Hilsenbeck SG, Osborne CK, O'Connell P, et al. The progression of DCIS to IBC: a cDNA expression microarray study [abstract 288]. Breast Cancer Res Treat 2002;288:S36.
198. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 2003;100:5974-9.
199. Porter D, Lahti-Domenici J, Keshaviah A, Bae YK, Argani P, Marks J, et al. Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res 2003;1:362-75.
200. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 2002;347:1999-2009.
201. Wulfkuhle JD, Sgroi DC, Krutzsch H, McLean K, McGarvey K, Knowlton M, et al. Proteomics of human breast ductal carcinoma in situ. Cancer Res 2002;62:6740-9.
202. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med 2004;350:1430-41.
203. Morrow M, Strom EA, Bassett LW, Dershaw DD, Fowble Harris JR, et al. Standard for the management of ductal carcinoma in situ of the breast (DCIS). CA Cancer J Clin 2002;52:256-76.
204. Schwartz GF, Solin LJ, Olivotto IA, Ernster VL, Pressman PI. Consensus conference on the treatment of in situ ductal carcinoma of the breast, April 22-25, 1999. Cancer 2000;88:946-54.
205. Schwartz GF. The current treatment of ductal carcinoma in situ. Breast J. 2001;7:308-10.
206. Boyages J, Delaney G, Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer 1999;85: 616-28.
207. Silverstein MJ, Barth A, Poller DN, Gierson ED, Colburn WJ, Waisman JR, et al. Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur J Cancer 1995;31A:1425-7.
208. Silverstein MJ, Lagios MD, Martino S, Lewinsky BS, Craig PH, Beron PJ, et al. Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast. J Clin Oncol 1998:16;1367-73.
209. Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 2004;96: 443-8.
210. Schwartz GF, Terribile D. The treatment of ductal carcinoma in situ of the breast. Obstet Gynecol Clin North Am 2002;29:189-200.
211. Cox CE, Pendas S, Cox JM, Joseph E, Shons AR, Yeatman T, et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg 1998;227:645-51.
212. Cox CE, Jakub JW. Re: Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg 2002;68:500-2.
213. Silverstein MJ, Gierson ED, Colburn WJ, Rosser RJ, Waisman JR, Gamagami P. Axillary lymphadenectomy for intraductal carcinoma of the breast. Surg Gynecol Obstet 1991;172:211-4.
214. Sakorafas GH, Tsiotou AG. Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives. Cancer Treat Rev 2000;26:103-25.
215. Fisher B, Costantino J, Redmond C, Fisher E, Margolese R, Dimitrov N, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993;328: 1581-6.
216. Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998;16:441-52.
217. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 2001;28:400-18.
218. Julien JP, Bijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomized phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000;355:528-33.
219. George WD, Houghton J, Cuzick J, Forbes J. Radiotherapy and tamoxifen following complete local excision (CLE) in the management of ductal carcinoma in situ (DCIS): preliminary results from the UK DCIS trial [abstract 270]. Proc ASCO 2000;19:70a.
220. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomized controlled trial. Lancet 2003;362:95-102.
221. Fisher B, Constantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-84.
222. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet 1999;353:1993-2000.
223. Dignam JJ, Fisher B. Occurrence of stroke with tamoxifen in NSABP B-24. Lancet 2000;355:848-9.
224. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362: 362-9.
225. Shimizu D, Ishikawa T, Ichikawa Y, Togo S, Hayasiazaki Y, Okazaki Y, et al. Current progress in the prediction of chemosensitivity for breast cancer. Breast Cancer 2004;11:42-8.
226. O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, et al. Treatment and prevention of intraepithelial neoplasia: An important target for accelerated new agent development. Recommendations of the American Association for Cancer Research Task Force on the treatment and prevention of intraepithelial neoplasia. Clin Cancer Res 2002;8:314-46.